The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.

摘要: Objective: Because of poor overall survival in advanced ovarian malignancies, patients often turn to alternative therapies despite controversy surrounding their use. Currently, the majority cancer combine some form complementary and medicine with conventional therapies. Of these therapies, antioxidants, added chemotherapy, are a frequent choice. Methods: For this preliminary report, two epithelial were studied. One patient had Stage IIIC papillary serous adenocarcinoma, other mixed seromucinous adenocarcinoma. Both optimally cytoreduced prior first-line carboplatinum/ paclitaxel chemotherapy. Patient 2 delay initiation chemotherapy secondary co-morbid conditions evidence for progression disease institution therapy. 1 began oral high-dose antioxidant therapy during her first month This consisted vitamin C, E, beta-carotene, coenzyme Q-10 multivitamin/mineral complex. In addition therapy, parenteral ascorbic acid at total dose 60 grams given twice weekly end consolidation antioxidants just beginning including received six cycles paclitaxel/carboplatinum refused radiographic persistent disease. Instead, she elected add intravenous weekly. gave written consent use records report. Results: normalization CA-125 after cycle has remained normal, almost 3 ⁄ years diagnosis. CT scans abdomen pelvis remain without recurrence. After round was noted have residual pelvis. She declined further acid. There is no recurrent by physical examination, normal three Conclusion: Antioxidants, when adjunctively, may improve efficacy prove be safe. A review four common follows. positive results found patients, randomized controlled trial now underway University Kansas Medical Center evaluating safety newly diagnosed cancer.